Physician profile
Michael A Kwiat
NPI 1366491094
$390,255.84
in general payments reported to CMS, 2019-2025
28 companies · $67K in 2025
The $67K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $22K · 2021: $23K · 2022: $62K · 2023: $56K · 2024: $63K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Travel and Lodging: $28K · Consulting Fee: $17K · Food and Beverage: $12K · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,771.75 |
| Travel and Lodging | $28,036.24 |
| Consulting Fee | $16,900.50 |
| Food and Beverage | $12,342.88 |
| Education | $129.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $129,627.53 | 2019-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $96,630.89 | 2019-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $89,084.85 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Avanir Pharmaceuticals, INC. | $58,723.69 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,803.53 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $2,744.98 | 2022-2025 | Auvelity |
| Abbvie INC. | $1,432.21 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,241.16 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,181.29 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,004.08 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $973.22 | 2019-2025 | Trintellix |
| Lundbeck LLC | $886.60 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $698.80 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $414.58 | 2019-2025 | Aplenzin, Wellbutrin |
| Allergan, INC. | $350.89 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $314.65 | 2019-2024 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $222.15 | 2022-2023 | Quviviq |
| Almatica Pharma LLC | $218.11 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Sage Therapeutics, LLC | $163.26 | 2024-2025 | Zurzuvae |
| Indivior INC. | $148.97 | 2019-2021 | |
| Biogen, INC. | $118.15 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $87.96 | 2021-2022 | |
| Eisai INC. | $71.46 | 2020-2022 | |
| Alfasigma USA, INC. | $44.07 | 2020 | |
| Supernus Pharmaceuticals, INC. | $24.38 | 2025 | Qelbree |
| Ucb, INC. | $17.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.10 | 2019 | |
| Merck Sharp & Dohme LLC | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kwiat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.